莱西康制药

最新新闻

• Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $3.1
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $1.2
  \u5e02\u573a\u8d44\u8baf · 2024/11/28
• 评级变动
  Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $1.9
  \u5e02\u573a\u8d44\u8baf · 2025/11/7
• 评级变动
  H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $6
  \u5e02\u573a\u8d44\u8baf · 2026/3/6
• 评级变动
  Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI) and Lexicon Pharmaceuticals (LXRX)
  TipRanks · 2024/11/13
• 评级变动
  Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $2.3
  \u5e02\u573a\u8d44\u8baf · 2026/3/10
• Cantor Fitzgerald Initiates Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Announces Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, Vs. FactSet Est of $0.05 Loss
  MT Newswires · 2026/8/6
• 评级变动
  Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $6
  \u5e02\u573a\u8d44\u8baf · 2025/5/15
• 评级变动
  Leerink Partners Maintains Lexicon Pharmaceuticals(LXRX.US) With Hold Rating, Maintains Target Price $1
  \u5e02\u573a\u8d44\u8baf · 2025/3/11
• H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• 评级变动
  Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2024/11/13
• 评级变动
  Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $1.9
  \u5e02\u573a\u8d44\u8baf · 2025/8/7
• 评级变动
  Needham Maintains Lexicon Pharmaceuticals(LXRX.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2025/3/7
• 评级变动
  H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $6
  \u5e02\u573a\u8d44\u8baf · 2024/11/1
• 评级变动
  Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Lexicon Pharmaceuticals (LXRX) and Carlsmed, Inc. (CARL)
  TipRanks · 2026/4/15
• 评级变动
  Leerink Partners Downgrades Lexicon Pharmaceuticals(LXRX.US) to Hold Rating, Announces Target Price $1
  \u5e02\u573a\u8d44\u8baf · 2025/3/5
• 评级变动
  H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $4
  \u5e02\u573a\u8d44\u8baf · 2026/1/22
• Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $3.1
  \u5e02\u573a\u8d44\u8baf · 2026/9/11

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。